GSK-3β is an important target for the treatment of AD because it acts as a linker between the two important histopathological hallmarks: NFTs formed by the accumulation of hyper-phosphorylated tau protein, and the extracellular senile plaques caused by abnormal Aβ aggregation. The gene discussed is GSK3B; the disease is Alzheimer disease.